Climate Change and American Bullfrog Invasion: What Could We Expect in South America? by Javier Nori (204103)

“…We also overlaid projected models onto the South American network of protected areas. Our results indicate a slight decrease in potential suitable area for bullfrog invasion, although protected areas will become more climatically suitable. …”

Dexra pretreatment prevents DXR-induced decrease in mice survivorship through 8 months of life. by Jenna Kropp (435547)

2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D₁ Receptor for... by Javier García-Cárceles (2073898)

“…In search for selective modulators of the D₁ receptor, the screening of a chemical library and subsequent medicinal chemistry program around an identified hit resulted in new synthetic compound <b>26</b> [UCM-1306, 2-(fluoromethoxy)-4′-(<i>S</i>-methanesulfonimidoyl)-1,1′-biphenyl] that increases the dopamine maximal effect in a dose-dependent manner in human and mouse D₁ receptors, is inactive in the absence of dopamine, modulates dopamine affinity for the receptor, exhibits subtype selectivity, and displays low binding competition with orthosteric ligands. …”

2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D₁ Receptor for... by Javier García-Cárceles (2073898)

“…In search for selective modulators of the D₁ receptor, the screening of a chemical library and subsequent medicinal chemistry program around an identified hit resulted in new synthetic compound <b>26</b> [UCM-1306, 2-(fluoromethoxy)-4′-(<i>S</i>-methanesulfonimidoyl)-1,1′-biphenyl] that increases the dopamine maximal effect in a dose-dependent manner in human and mouse D₁ receptors, is inactive in the absence of dopamine, modulates dopamine affinity for the receptor, exhibits subtype selectivity, and displays low binding competition with orthosteric ligands. …”

2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D₁ Receptor for... by Javier García-Cárceles (2073898)

“…In search for selective modulators of the D₁ receptor, the screening of a chemical library and subsequent medicinal chemistry program around an identified hit resulted in new synthetic compound <b>26</b> [UCM-1306, 2-(fluoromethoxy)-4′-(<i>S</i>-methanesulfonimidoyl)-1,1′-biphenyl] that increases the dopamine maximal effect in a dose-dependent manner in human and mouse D₁ receptors, is inactive in the absence of dopamine, modulates dopamine affinity for the receptor, exhibits subtype selectivity, and displays low binding competition with orthosteric ligands. …”

2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D₁ Receptor for... by Javier García-Cárceles (2073898)

“…In search for selective modulators of the D₁ receptor, the screening of a chemical library and subsequent medicinal chemistry program around an identified hit resulted in new synthetic compound <b>26</b> [UCM-1306, 2-(fluoromethoxy)-4′-(<i>S</i>-methanesulfonimidoyl)-1,1′-biphenyl] that increases the dopamine maximal effect in a dose-dependent manner in human and mouse D₁ receptors, is inactive in the absence of dopamine, modulates dopamine affinity for the receptor, exhibits subtype selectivity, and displays low binding competition with orthosteric ligands. …”

2‑(Fluoromethoxy)-4′‑(<i>S</i>‑methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D₁ Receptor for... by Javier García-Cárceles (2073898)

“…In search for selective modulators of the D₁ receptor, the screening of a chemical library and subsequent medicinal chemistry program around an identified hit resulted in new synthetic compound <b>26</b> [UCM-1306, 2-(fluoromethoxy)-4′-(<i>S</i>-methanesulfonimidoyl)-1,1′-biphenyl] that increases the dopamine maximal effect in a dose-dependent manner in human and mouse D₁ receptors, is inactive in the absence of dopamine, modulates dopamine affinity for the receptor, exhibits subtype selectivity, and displays low binding competition with orthosteric ligands. …”

Parasite Load Decrease during Application of a Safe and Easily Applied Antileishmanial Aminoglycoside Cream by Afif Ben Salah (202439)

<i>A</i>. <i>persici</i>-conditioned diet shortens lifespan. by Taro Onuma (15195377)

<i>Symbiodinium</i> density <i>in hospite</i>. by Lisa Fujise (672628)

Non-hydrolysable ATP analogues prevent decrease of I_Ca,L by metabolic inhibition. by Giedrius Kanaporis (4405525)

Fig 3 - by Hyun-Jun Kim (1561153)

“…E) Densitometry analysis of atrogin-1, MuRF-1, mTOR and phosphorylated mTOR expression. ** = <i>p</i><0.01 indicates significantly decreased or increased expression compared to the untreated control (n = 4).…”

The biliary injuries and cholestasis are alleviated by the decreased pro-inflammatory activation of macrophages treated with InCsEVs. by Beibei Zhang (509356)

CFDP1 and H2A.Z co-bound peaks. by Gokul Gopinathan (7930679)

Subjects:

Poly(I:C) at a low dose inhibits <i>A</i>. <i>flavus</i> induced AHR and acute eosinophilia. by Li She (2204779)

“…Administration of Poly(I:C) decreased the percentage and number of eosinophils in lungs after exposure to <i>A</i>. …”

Fig 6 - by Hyun-Jun Kim (1561153)

“…The IC₅₀ 3.49 μM, 2.94 μM, and 3.07 μM, respectively. ** = <i>p</i><0.01 and **** = <i>p</i><0.0001 indicate significantly decreased viability compared to the untreated control. …”

Fig 2 - by Hyun-Jun Kim (1561153)

“…Myoblasts were differentiated for 72 h and treated with 10 μM Dex, or 10 μM Dex plus 300 nM or 600 nM Ni or 50 ng/ml bovine insulin for 24 h. B) Average diameter of C2C12 myotubes treated with Dex or Dex+Ni. *** = <i>p</i><0.001 indicate significantly decreased compared to the untreated control. ### = <i>p</i><0.001 to indicate significantly increased myotube diameter compared to Dex treated myotubes. …”

<i>Orobanche</i> incidence (%) and <i>Orobanche</i> severity (1–9), Number of Days to <i>Orobanche</i> Emergence (NDOE) and number of Emerged Orobanche Shoots per plant (EOS) recor... by Moez Amri (10872935)

Subjects:

Everolimus decreased EC inflammation via lowered IL-1β and IL-6 expression in ECs. by Zsolt Fejes (844136)

Mean trans-epidermal water loss (TEWL) (a) and pH (b) and decrease in mRNA expression (c) in the AD <i>FLG</i>+/+, AD <i>FLG</i>+/− and the AD/IV <i>FLG</i>−/− group. by Mårten C. G. Winge (118591)